These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

239 related articles for article (PubMed ID: 30235108)

  • 1. Is Procalcitonin Biomarker-Guided Antibiotic Therapy a Cost-Effective Approach to Reduce Antibiotic Resistant and Clostridium difficile Infections in Hospitalized Patients?
    Steuten L; Mewes J; Lepage-Nefkens I; Vrijhoef H
    OMICS; 2018 Sep; 22(9):616-625. PubMed ID: 30235108
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Procalcitonin Biomarker Algorithm Reduces Antibiotic Prescriptions, Duration of Therapy, and Costs in Chronic Obstructive Pulmonary Disease: A Comparison in the Netherlands, Germany, and the United Kingdom.
    van der Maas ME; Mantjes G; Steuten LM
    OMICS; 2017 Apr; 21(4):232-243. PubMed ID: 28388301
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The cost impact of PCT-guided antibiotic stewardship versus usual care for hospitalised patients with suspected sepsis or lower respiratory tract infections in the US: A health economic model analysis.
    Mewes JC; Pulia MS; Mansour MK; Broyles MR; Nguyen HB; Steuten LM
    PLoS One; 2019; 14(4):e0214222. PubMed ID: 31013271
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cost-Effectiveness Analysis of a Procalcitonin-Guided Decision Algorithm for Antibiotic Stewardship Using Real-World U.S. Hospital Data.
    Voermans AM; Mewes JC; Broyles MR; Steuten LMG
    OMICS; 2019 Oct; 23(10):508-515. PubMed ID: 31509068
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A PCT algorithm for discontinuation of antibiotic therapy is a cost-effective way to reduce antibiotic exposure in adult intensive care patients with sepsis.
    Kip MM; Kusters R; IJzerman MJ; Steuten LM
    J Med Econ; 2015; 18(11):944-53. PubMed ID: 26105574
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cost-effectiveness of procalcitonin testing to guide antibiotic treatment duration in critically ill patients: results from a randomised controlled multicentre trial in the Netherlands.
    Kip MMA; van Oers JA; Shajiei A; Beishuizen A; Berghuis AMS; Girbes AR; de Jong E; de Lange DW; Nijsten MWN; IJzerman MJ; Koffijberg H; Kusters R
    Crit Care; 2018 Nov; 22(1):293. PubMed ID: 30424796
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Procalcitonin testing to guide antibiotic therapy for the treatment of sepsis in intensive care settings and for suspected bacterial infection in emergency department settings: a systematic review and cost-effectiveness analysis.
    Westwood M; Ramaekers B; Whiting P; Tomini F; Joore M; Armstrong N; Ryder S; Stirk L; Severens J; Kleijnen J
    Health Technol Assess; 2015 Nov; 19(96):v-xxv, 1-236. PubMed ID: 26569153
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Analysis to determine cost-effectiveness of procalcitonin-guided antibiotic use in adult patients with suspected bacterial infection and sepsis.
    Collins CD; Brockhaus K; Sim T; Suneja A; Malani AN
    Am J Health Syst Pharm; 2019 Aug; 76(16):1219-1225. PubMed ID: 31369118
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Budget impact analysis of using procalcitonin to optimize antimicrobial treatment for patients with suspected sepsis in the intensive care unit and hospitalized lower respiratory tract infections in Argentina.
    Garay OU; Guiñazú G; Cornistein W; Farina J; Valentini R; Levy Hara G
    PLoS One; 2021; 16(4):e0250711. PubMed ID: 33930050
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Introduction of a PCT-based algorithm to guide antibiotic prescription in COPD exacerbation.
    Picart J; Moiton MP; Gaüzère BA; Gazaille V; Combes X; DiBernardo S
    Med Mal Infect; 2016 Dec; 46(8):429-435. PubMed ID: 27609596
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Procalcitonin-guided antibiotic therapy in patients with fever in a general emergency department population: a multicentre non-inferiority randomized clinical trial (HiTEMP study).
    van der Does Y; Limper M; Jie KE; Schuit SCE; Jansen H; Pernot N; van Rosmalen J; Poley MJ; Ramakers C; Patka P; van Gorp ECM; Rood PPM
    Clin Microbiol Infect; 2018 Dec; 24(12):1282-1289. PubMed ID: 29870855
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Procalcitonin-Guided Treatment on Duration of Antibiotic Therapy and Cost in Septic Patients (PRODA): a Multi-Center Randomized Controlled Trial.
    Jeon K; Suh JK; Jang EJ; Cho S; Ryu HG; Na S; Hong SB; Lee HJ; Kim JY; Lee SM
    J Korean Med Sci; 2019 Apr; 34(14):e110. PubMed ID: 30977312
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Procalcitonin to Reduce Long-Term Infection-associated Adverse Events in Sepsis. A Randomized Trial.
    Kyriazopoulou E; Liaskou-Antoniou L; Adamis G; Panagaki A; Melachroinopoulos N; Drakou E; Marousis K; Chrysos G; Spyrou A; Alexiou N; Symbardi S; Alexiou Z; Lagou S; Kolonia V; Gkavogianni T; Kyprianou M; Anagnostopoulos I; Poulakou G; Lada M; Makina A; Roulia E; Koupetori M; Apostolopoulos V; Petrou D; Nitsotolis T; Antoniadou A; Giamarellos-Bourboulis EJ
    Am J Respir Crit Care Med; 2021 Jan; 203(2):202-210. PubMed ID: 32757963
    [No Abstract]   [Full Text] [Related]  

  • 14. Procalcitonin-guided antibiotic therapy for chronic obstructive pulmonary disease exacerbations.
    Tokman S; Schuetz P; Bent S
    Expert Rev Anti Infect Ther; 2011 Jun; 9(6):727-35. PubMed ID: 21692680
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Point-of-care procalcitonin test to reduce antibiotic exposure in patients hospitalized with acute exacerbation of COPD.
    Corti C; Fally M; Fabricius-Bjerre A; Mortensen K; Jensen BN; Andreassen HF; Porsbjerg C; Knudsen JD; Jensen JU
    Int J Chron Obstruct Pulmon Dis; 2016; 11():1381-9. PubMed ID: 27382274
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The budget impact of procalcitonin-guided antibiotic stewardship compared to standard of care for patients with suspected sepsis admitted to the intensive care unit in Belgium.
    Garnfeldt VM; Vincent JL; Gruson D; Garay OU; Vansieleghem S; Iniguez L; Lefevre A
    PLoS One; 2023; 18(10):e0293544. PubMed ID: 37903106
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Potential of serum procalcitonin in predicting bacterial exacerbation and guiding antibiotic administration in severe COPD exacerbations: a systematic review and meta-analysis.
    Ni W; Bao J; Yang D; Xi W; Wang K; Xu Y; Zhang R; Gao Z
    Infect Dis (Lond); 2019 Sep; 51(9):639-650. PubMed ID: 31355690
    [No Abstract]   [Full Text] [Related]  

  • 18. Is procalcitonin-guided antimicrobial use cost-effective in adult patients with suspected bacterial infection and sepsis?
    Harrison M; Collins CD
    Infect Control Hosp Epidemiol; 2015 Mar; 36(3):265-72. PubMed ID: 25695167
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Procalcitonin algorithm to guide initial antibiotic therapy in acute exacerbations of COPD admitted to the ICU: a randomized multicenter study.
    Daubin C; Valette X; Thiollière F; Mira JP; Hazera P; Annane D; Labbe V; Floccard B; Fournel F; Terzi N; Du Cheyron D; Parienti JJ;
    Intensive Care Med; 2018 Apr; 44(4):428-437. PubMed ID: 29663044
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact of Procalcitonin Guidance on Management of Adults Hospitalized with Chronic Obstructive Pulmonary Disease Exacerbations.
    Bremmer DN; DiSilvio BE; Hammer C; Beg M; Vishwanathan S; Speredelozzi D; Moffa MA; Hu K; Abdulmassih R; Makadia JT; Sandhu R; Naddour M; Chan-Tompkins NH; Trienski TL; Watson C; Obringer TJ; Kuzyck J; Walsh TL
    J Gen Intern Med; 2018 May; 33(5):692-697. PubMed ID: 29404940
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.